% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

  • vincenzo01 vincenzo01 Oct 3, 2013 12:54 PM Flag

    Large holder of Osir releases prelim year-end report

    Earlier today a fellow poster noted a burst of buying in NEW VENTURE TEC which holds over 4 million shares of OSIR. The following release today, from Switzerland may have something to do with that.

    Press Release
    For further information:

    October3 2013
    Yves Huwyler
    Hinterbergstrasse 47
    6312 Steinhausen
    Tel: 041 740 26 26
    Email: yves.
    New Venturetec
    Result expectation for the fiscal year 2012/2013
    ended September 30, 2013

    Zug,October3, 2013

    New Venturetec ended its fiscal year 2012/13 on September 30,2013. Based on the current valuations of the portfolio companies New Venturetec expects a consolidated net gain of approximately USD 16,500,000
    or USD 3.30 per share. The main reason for the gain is the increase of the traded share price of Osiris Therapeutics from USD 11.05 per share to USD 16.64 per share in the reporting period.

    The estimated numbers could change materially during the course of the end year valuation process of
    the portfolio, which will be done in the coming weeks. The final annual financials, together
    with the annual report of New Venturetec 2012/13 will be published on November 13, 2013.

    New Venturetec did not give any guidance on its performance for the fiscal year 2012/13
    and has never done so in the past. New Venturetec is a publicly traded Swiss investment company (SIX:NEV) which invests directly inventure capital companiesin the area of biotechnology and technology
    in the USA.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.74+0.13(+2.32%)3:59 PMEDT